Evidence map›Paper›PMID 37791761›Full record

ArticleJournal of clinical microbiology2023

Rapid Aztreonam/Avibactam NP test for detection of aztreonam/avibactam susceptibility/resistance in Enterobacterales.

Clément Viguier, Maxime Bouvier, Mustafa Sadek, Auriane Kerbol, Laurent Poirel, Patrice Nordmann

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Breathe (Sheffield, England) · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 3 countries.

Clément ViguierEmerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg, Switzerland.ORCID 0000-0002-3270-178X
Maxime BouvierEmerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg, Switzerland.
Mustafa SadekEmerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg, Switzerland.
Auriane KerbolSwiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg , Fribourg, Switzerland.
Laurent PoirelEmerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg, Switzerland.
Patrice NordmannEmerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg, Switzerland.ORCID 0000-0002-1343-1622
University of Fribourg · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aztreonam-avibactam (AZA), a newly developed β-lactam/β-lactamase inhibitor combination

Indexed as

Anti-Bacterial AgentsAztreonamAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesCeftazidimeDrug CombinationsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-LactamasesCeftazidimeDrug CombinationsAztreonam-avibactamdiagnosticsEnterobacteralesmonobactamrapidresistance

Identifiers

PMID37791761
PMCPMC10595063
OpenAlexW4387326331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.